Year: 2025

SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference. iRhythm’s management is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Events and Presentations” section of the company’s investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc.iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based...

CHICAGO, Dec. 29, 2025 (GLOBE NEWSWIRE) — XA Investments LLC (“XAI”), a leader in closed-end interval and tender offer fund research, announced it plans to expand the XAI Interval Fund Index™ (“INTVL”) suite with its first sub-index. Expected to launch in Q1 2026, the XAI Interval Fund Credit Index™ (“INTVL-C”) will track the performance of credit interval and tender offer funds. The sub-index will offer asset managers greater transparency with a more comprehensive look at category constituents that have not been offered before. INTVL-C will provide fund sponsors with valuable performance metrics to improve investment decisions and risk assessment in credit funds, while enabling better fund comparisons through a dedicated benchmark. “INTVL-C is instrumental in helping fund managers benchmark credit interval funds...

VANCOUVER, British Columbia, Dec. 29, 2025 (GLOBE NEWSWIRE) — A.I.S. Resources Limited (TSXV: AIS, OTC- PINK: AISSF) (“AIS” or the “Company”) announces that the TSX Venture Exchange (the “Exchange” or the “TSXV”) has accepted the Company’s application for reinstatement to trading. The Company expects that its common shares will be reinstated for trading on the TSXV on or about January 2, 2026. Following the November 14, 2025 revocation of the Company’s failure-to-file cease trade order by the BCSC the Company applied on November 19, 2025 for reinstatement to trading with the TSX Venture Exchange. (the “Exchange”). In connection with the application for reinstatement to trading the Company has undergone an Exchange review which is now completed. The Company acknowledges and appreciates the patience of its shareholders and stakeholders...

Aspo Plc  ANNOUNCEMENT  29.12.2025          Aspo Plc: Share repurchase 29.12.2025       In the Helsinki Stock Exchange         Trade date           29.12.2025  Bourse trade         Buy  Share                  ASPO  Amount             2 500 SharesAverage price/ share    6,4720 EURTotal cost            16 180,00 EUR          Aspo Plc now holds a total of 105 500 shares  including the shares repurchased on 29.12.2025       The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5and the Commission Delegated Regulation (EU) 2016/1052.          On behalf of Aspo Plc         Nordea Bank Oyj              Sami Huttunen Ilari Isomäki       For more information, please contact:  Erkka...

Interim information of Grigeo Group AB will be prepared and financial results will be released on these dates: February 25, 2026 – Interim Financial Statements for 12 months of 2025.April 7, 2026 – Annual audited Financial Statements for the year 2025.May 25, 2026 – Interim Financial Statements for 3 months of 2026.August 25, 2026 – Interim Financial Statements for 6 months of 2026.November 24, 2026 – Interim Financial Statements for 9 months of 2026. On April 30, 2026, the Company plans to hold an ordinary general meeting of shareholders. Tomas JozonisChief Executive Officer+370 5 243 58 01

Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001’s Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN) Dear Valued Shareholders, 2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovarian Cancer Treatment As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data validation, and strategic execution that has significantly strengthened IMUNON’s position. Our focus on harnessing the power to activate the body’s immune system against cancer has yielded compelling results, bringing us closer to delivering innovative therapies that could transform patient outcomes and create substantial...